Upstream Bio is developing verekitug, a clinical-stage monoclonal antibody that targets an upstream driver of inflammatory response to treat severe asthma. This therapy aims to provide improved treatment options for patients suffering from this chronic respiratory condition.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ESVHFounders
Product
Problem
Severe asthma, a chronic inflammatory respiratory condition, often lacks effective treatment options, leaving millions of patients with unmet needs. Current therapies may not adequately address the underlying drivers of inflammation, resulting in suboptimal disease control and persistent symptoms.
Solution
Upstream Bio is developing verekitug, a clinical-stage monoclonal antibody that targets an upstream driver of inflammatory response. Verekitug's unique mechanism of action aims to improve treatment options for patients suffering from severe inflammatory diseases, particularly severe asthma. By targeting the root cause of inflammation, this therapy has the potential to provide more effective and durable disease control compared to existing treatments. The company is committed to leveraging verekitug to address the unmet needs of patients living with these conditions.
Target Audience
The primary target audience includes patients suffering from severe asthma and other inflammatory diseases, as well as the healthcare providers who treat them.
Features
- Verekitug: A clinical-stage monoclonal antibody
- Targets an upstream driver of inflammatory response
- Designed for the treatment of severe inflammatory diseases, with an initial focus on severe asthma